Incidence, risk factors, and clinical outcome of stroke after acute myocardial infarction in clinical practice☆
References (12)
- et al.
Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction
Am J Med
(1988) - et al.
Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomesa nationwide perspective of current clinical practice
Am Heart J
(1998) - et al.
Individual risk assessment for intracranial haemorrhage during thrombolytic therapy
Lancet
(1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
N Engl J Med
(1993)Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarctionISIS-2
Lancet
(1988)A randomised comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected acute myocardial infarction
Lancet
(1992)
There are more references available in the full text version of this article.
Cited by (0)
- ☆
This study was supported in part by AstraZeneca, Wedel, Germany; Bristol-Myers Squibb, München, Germany; Knoll AG, Ludwigshafen, Germany; the Landesversichenrungsanstalt, Rheinland-Pfalz, Germany; and the Ministerum für Arbeit, Soziales und Gesundheit, Rheinland-Pfalz, Germany.
Copyright © 2001 Excerpta Medica Inc. All rights reserved.